Navigation Links
Luminex Corporation Third Quarter Earnings Release Scheduled for November 1, 2011
Date:10/11/2011

AUSTIN, Texas, Oct. 11, 2011 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) today announced that it expects to report results for the third quarter of 2011 on Tuesday, November 1, 2011.  A press release announcing the results is scheduled for release after the close of trading.

(Logo:  http://photos.prnewswire.com/prnh/20100104/LUMINEXLOGO)

Management will hold a conference call to discuss the operating highlights and financial results for the third quarter ended September 30, 2011, at 5:00 p.m. Eastern time on November 1, 2011.

The conference call will be webcast live and will be accompanied by a slide presentation, both of which may be accessed at Luminex Corporation's website at http://www.luminexcorp.com.  Simply log on to the website, go to the About Us section and access the Investor Relations link.  Please go to the website at least 15 minutes prior to the call to register, download and install any necessary audio/video software.  If you are unable to participate during the live webcast, the call and slides will be archived for six months on the website using the 'replay' link.

The use of pop-up blocking software may impair your ability to view webcasts.  If you use this software, press and hold the CTRL key when you click on the Register button.  Please contact your IT group if you are unable to override this feature.  Unauthorized recording or downloading of this event is not permitted.

About Luminex Corporation

Luminex Corporation develops, manufactures and markets proprietary biological testing technologies with applications throughout the diagnostic and life sciences industries. The Company's xMAP® multiplex solutions include an open-architecture, multi-analyte technology platform that delivers fast, accurate and cost-effective bioassay results to markets as diverse as pharmaceutical drug discovery, clinical diagnostics and biomedical research, including the genomics and proteomics research markets. The Company's xMAP technology is sold worldwide and is already in use in leading clinical laboratories as well as major pharmaceutical, diagnostic and biotechnology companies. Further information on Luminex Corporation or xMAP technology can be obtained at www.luminexcorp.com.

Statements made in this release that express Luminex Corporation's or management's intentions, plans, beliefs, expectations or predictions of future events are forward-looking statements. The words "believe," "expect," "intend," "estimate," "anticipate," "will," "could," "should" and similar expressions are intended to further identify such forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. It is important to note that the Company's actual results or performance could differ materially from those anticipated or projected in such forward-looking statements. Factors that could cause Luminex's actual results or performance to differ materially include risks and uncertainties relating to, among others, market demand and acceptance of Luminex's products, the Company's dependence on strategic partners for development, commercialization and distribution of products, concentration of the Company's revenue in a limited number of strategic partners, fluctuations in quarterly results due to a lengthy and unpredictable sales cycle and bulk purchases of consumables, Luminex's ability to scale manufacturing operations and manage operating expenses, gross margins and inventory levels, potential shortages of components, competition, the timing of regulatory approvals, the implementation, including any modification, of the Company's strategic operating plans, risks and uncertainties associated with implementing our acquisition strategy and the ability to integrate acquired companies or selected assets into our consolidated business operations, as well as the risks discussed under the heading "Risk Factors" in Luminex's Reports on Forms 10-K and 10-Q, as filed with the Securities and Exchange Commission. The forward-looking statements contained herein represent the judgment of Luminex as of the date of this press release, and Luminex expressly disclaims any intent, obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in Luminex's expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.

Luminex Corporate Contact:

Harriss T. Currie
Chief Financial Officer and Vice President, Finance
512-219-8020
hcurrie@luminexcorp.com

Luminex Investor Relations Contact:

Matthew D. Scalo
Sr. Director of Investor Relations
512-219-8020
mscalo@luminexcorp.com


'/>"/>
SOURCE Luminex Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Luminex Corporation Hosts Ninth Annual Planet xMAP Europe in Vienna
2. Luminex Corporation to Present at Upcoming Investment Conferences In September
3. Luminex Corporation Reports Second Quarter 2011 Results
4. Luminex Corporation Receives U.S. FDA Clearance for New, Front Line Respiratory Viral Panel Test
5. Luminex Corporation Second Quarter Earnings Release Scheduled for August 8, 2011
6. Luminex Corporation Completes Acquisition of EraGen Biosciences, Inc.
7. Luminex Corporation Named Most Innovative Company of the Year and Receives Business Innovation of the Year Award for MAGPIX® System
8. Luminex Corporation Announces Agreement to Acquire EraGen Biosciences, Inc.
9. Luminex and Life Technologies Sign Agreement for Global Distribution of the Award-Winning MAGPIX® Multiplexing Instrument
10. Luminex Corporation to Present at Jefferies 2011 Global Healthcare Conference
11. Luminex Corporation Reports First Quarter 2011 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... 2017 New England Pediatric Device Consortium (NEPDC) ... including funding and in-kind service towards the commercialization of ... "Making blood draws less traumatic for children could ... experience better.  We,re looking forward to working with Velano ... care for the kids we treat," said Ann-Christine ...
(Date:3/24/2017)... YORK , March 24, 2017   ... leading organization within medical affairs in the pharmaceutical ... as the chair of a newly formed scientific ... board members to form the first ever medical ... For more information about the ACMA, please ...
(Date:3/24/2017)... Mar 24, 2017 Research and Markets has ... and Diagnostics, 2017 - 2035" report to their offering. ... The Deep Learning: Drug ... future outlook of the growing market of deep learning solutions within ... learning algorithms have emerged as a novel solution to generate relevant ...
Breaking Medicine Technology:
(Date:3/23/2017)... ... 23, 2017 , ... A recent report from the National Council on Teacher ... NCTQ report suggests, based on a review of GPA and SAT/ACT requirements at 221 ... the U.S. It argues that this higher bar should be set by states, by ...
(Date:3/23/2017)... ... March 23, 2017 , ... ... to their communities, 16 more public health departments have been awarded national accreditation ... another 4.5 million people into the expanding network of communities across the nation ...
(Date:3/23/2017)... ... March 23, 2017 , ... ... Center at 10 North Broadway Avenue, will be an educational and exciting program ... instruction in the management of chronic pain. , Oklahoma is in a healthcare ...
(Date:3/23/2017)... and Grimsby, Ontario (PRWEB) , ... March 23, 2017 , ... The MBI “Hall of ... industry or whose acts have had a significant impact on the careers of all others ... Marketing with NRB Inc. was inducted into the MBI’s Hall of Fame. The induction ...
(Date:3/23/2017)... ... March 23, 2017 , ... Dilger-Maxwell ... of the Norwalk and Vermillion areas, celebrates the newest charity campaign in ... nonprofit, community-based substance abuse prevention and peer recovery support organization providing vital ...
Breaking Medicine News(10 mins):